Mycophenolate mofetil for systemic sclerosis : Drug exposure exhibits considerable inter-individual variation-a prospective, observational study
Objective: Mycophenolate mofetil (MMF) is an established therapy for systemic sclerosis (SSc), but its pharmacokinetics in this disease remains unexplored. We have investigated drug exposure in MMF-Treated patients with SSc in relation to clinical features of the disease and common concomitant drugs. Methods: This study was predefined to include 35 MMF-Treated SSc patients who were using MMF at a